8-K
filed February 29, 2024, 6:59 PM ET
ticker ORGO
CIK 0001661181
earnings
confidence high
sentiment negative
materiality 0.75
Organogenesis Q4 revenue $99.7M (-14% YoY); net loss $0.6M; FY2024 guides $445M-$470M
Organogenesis Holdings Inc.
2023-FY EPS reported
$0.04
revenue$433,140,000
- Net revenue Q4 $99.7M (-14% YoY): Advanced Wound Care $93.2M (-14%), Surgical & Sports Medicine $6.5M (-3%).
- Q4 net loss $0.6M vs net income $7.5M; adjusted net income $1.9M vs $8.9M.
- FY2023 net income $4.9M vs $15.5M; adjusted EBITDA $42.6M vs $49.3M.
- FY2024 revenue guidance $445M-$470M (3%-9% growth); net income (loss) range ($10.6M)-$4.6M.
- Management highlights progress on ReNu program for knee osteoarthritis as key value driver.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Organogenesis Holdings Inc. reported the fourth quarter ended December 31, 2023 results: revenue $99.7 million, net income Net loss of $0.6 million.
- Period
- the fourth quarter ended December 31, 2023
- Revenue
- $99.7 million
- Net income
- Net loss of $0.6 million
- Result
- reported results
Exact text from the filing
Net revenue of $99.7 million for the fourth quarter of 2023
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Organogenesis Holdings Inc. reported the fiscal year ended December 31, 2023 results: revenue $433.1 million, net income Net income of $4.9 million. Guidance initiated.
- Period
- the fiscal year ended December 31, 2023
- Revenue
- $433.1 million
- Net income
- Net income of $4.9 million
- Guidance
- initiated
- Result
- reported results
Exact text from the filing
Net revenue of $433.1 million for the year ended December 31, 2023
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.